Dissertation Carolin Grundgeiger - TOBIAS-lib - Universität Tübingen

124
Literaturverzeichnis
6 Literaturverzeichnis
1. World Health Organisation: Ten statistical highlights in global public
health. Geneva 2006;
http://www.who.int/whosis/whostat2006_10highlights.pdf
(eingelesen September 2007)
2. World Health Organisation: Preventing chronic diseases: a vital
investment. Geneva 2005;
http://whqlibdoc.who.int/publications/2005/9241563001_eng.pdf
(eingelesen September 2007)
3. Statistisches Bundesamt: Herzkreislauferkrankung bleibt häufigste
Todesursache. Pressemitteilung Nr 383 vom15.9.2006;
http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Pre
sse/pm/2006/09/PD06__383__232,templateId=renderPrint.psml
(eingelesen September 2007)
4. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med
1999;340:115-126
5. Lusis AJ: Atherosclerosis. Nature 2000;407:233-241
6. Shin J, Johnson JA: Pharmacogenetics of beta-blockers.
Pharmacotherapy 2007;27:874-887
7. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality
among high-risk and low-risk patients after myocardial infarction. N Engl
J Med 1998;339:489-497
8. Egan BM, Basile J, Chilton RJ, Cohen JD: Cardioprotection: the role of
beta-blocker therapy. J Clin Hypertens 2005;7:409-416
9. Kennedy HL: Current utilization trends for beta-blockers in
cardiovascular disease. Am J Med 2001;110 Suppl 5A:2S-6S
10. Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and
pharmacological characteristics. Int J Clin Pharmacol Ther 2006;44:344-
357
11. Brixius K, Bundkirchen A, Bolck B, Mehlhorn U, Schwinger RH:
Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic
sympathomimetic activity in human myocardium. Br J Pharmacol
2001;133:1330-1338
12. Berlin-Chemie Menarini: Fachinformation zu Nebilet®, Stand: November
2004. Berlin 2004